ImmuCell Corporation Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
ImmuCell Corporation (ICCC) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $5.79 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-03-30
- ImmuCell Corporation share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $5.15, a 1.34% decline year-over-year.
- ImmuCell Corporation share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $5.22, a 36.11% decline year-over-year.
- ImmuCell Corporation share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2022-03-31 was $8.17.
- ImmuCell Corporation share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2017-03-31 was $5.84.
- ImmuCell Corporation share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $5.79.
- ImmuCell Corporation share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $5.16, a 33.25% decline from fiscal 2022.
- ImmuCell Corporation share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $7.73, a 20.96% decline from fiscal 2021.
- ImmuCell Corporation share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2021 was $9.78.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2025-12-31 | $5.79 10-K · filed 2026-03-30 | |||
| 2025-09-30 | $5.67 10-Q · filed 2025-11-13 | |||
| 2024-12-31 | $3.91 10-Q · filed 2025-11-13 | |||
| 2024-09-30 | $3.80 10-Q · filed 2024-11-13 | |||
| 2024-06-30 | $4.30 10-Q · filed 2024-08-13 | |||
| 2024-03-31 | $5.15 10-Q · filed 2024-05-14 | |||
| 2023-12-31 | $5.16 10-K · filed 2025-03-28 | |||
| 2023-09-30 | $5.19 10-Q · filed 2023-11-13 | |||
| 2023-06-30 | $5.19 10-Q · filed 2023-08-10 | |||
| 2023-03-31 | $5.22 10-Q · filed 2023-05-11 | |||
| 2022-12-31 | $7.73 10-K · filed 2024-04-01 | |||
| 2022-09-30 | $8.14 10-Q · filed 2022-11-21 | |||
| 2022-06-30 | $8.25 10-Q/A · filed 2022-11-21 | |||
| 2022-03-31 | $8.17 10-Q/A · filed 2022-11-21 | |||
| 2021-12-31 | $9.78 10-K · filed 2023-03-29 | |||
| 2021-09-30 | $9.82 10-Q · filed 2021-11-15 | |||
| 2021-06-30 | $9.79 10-Q · filed 2021-08-12 | |||
| 2020-12-31 | $5.03 10-Q/A · filed 2022-11-21 | |||
| 2017-12-31 | $5.92 10-K · filed 2018-03-29 | |||
| 2017-09-30 | $5.85 10-Q · filed 2017-11-13 | |||
| 2017-06-30 | $5.83 10-Q · filed 2017-08-14 | |||
| 2017-03-31 | $5.84 10-Q · filed 2017-05-11 | |||
| 2016-12-31 | $6.98 10-K · filed 2018-03-29 | |||
| 2015-12-31 | $7.40 10-K · filed 2017-03-30 | |||
| 2014-12-31 | $4.69 10-K · filed 2015-03-26 | |||
| 2013-12-31 | $4.67 10-K · filed 2015-03-26 | |||
| 2012-12-31 | $5.93 10-K · filed 2015-03-26 | |||
| 2011-12-31 | $5.72 10-K · filed 2014-03-26 | |||
| 2010-12-31 | $3.48 10-K · filed 2013-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |